TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03543332

Intervention type: DIAGNOSTIC_TEST
Intervention: Measures of physical activity and kinesiophobia
Description: Groups will be compared regarding kinesiophobia with TSK heart.
Study: NCT02930759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
Study: NCT04170465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 mg Tablets
Description: Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC-T chemotherapy regimen
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-T chemotherapy regimen
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
Study: NCT01774162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine needle biopsy using ProCore needle for histology.
Description: EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration using conventional FNA for cytology
Description: EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
Study: NCT01647477

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: questionnaires to answer at baseline 45 minutes
Study: NCT01787123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cerebrolysin
Description: 14-day course of intravenous Cerebrolysin started within 4 days of ictus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 14-day course of intravenous normal saline started within 4 days of ictus
Study: NCT04121637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frenkel coordination exercises
Description: Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel coordination exercises
Description: Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
Study: NCT01513824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pressure pain sensitivity measure followed bu acupressure
Description: twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
Study: NCT02567240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon monoxide-bubbled mediums
Description: Islets will be harvested with carbon monoxide bubbled mediums
Study: NCT01392235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: 25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT04269525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
Study: NCT00805142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
Study: NCT04441151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation therapy
Description: Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
Study: NCT02559180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
Study: NCT00070551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT00867906

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat-PAD
Description: Cat-PAD dose 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat-PAD
Description: Cat-PAD dose 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat-PAD
Description: Cat-PAD dose 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo comparator, 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo comparator, 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo comparator, 1x8 administrations 2 weeks apart
Study: NCT03331523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate
Description: Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex®
Description: Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
Study: NCT00070551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT01140165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cheese
Description: the effect of cheese intake versus butter intake on blood lipids (primarily)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheese
Description: the effect of cheese intake versus butter intake on blood lipids (primarily)
Study: NCT03997773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-it Intervention
Description: The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
Study: NCT02145715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00986362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 175µg ocriplasmin intravitreal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravitreal injection
Study: NCT00812565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% isotonic sodium chloride solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% isotonic sodium chloride solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
Study: NCT03824093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFIX Only
Description: The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFIX+ Provider Communication Training
Description: The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
Study: NCT00375518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
Study: NCT02469519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone - ACTIVE
Description: antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - PLACEBO
Description: normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
Study: NCT00829959

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 1 - 2 questionnaires, lasting 10-15 minutes.
Study: NCT03539575

Intervention type: OTHER
Group type: OTHER
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Study: NCT01341028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass (LRYGBP)
Description: Twelve patients underwent laparoscopic Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LRYGBP+gastric fundus resection
Description: Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
Study: NCT02328027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128
Description: 1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
Study: NCT01189591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slow-wave deprivation
Description: Using acoustic tones to suppress slow-wave sleep
Study: NCT01736618

Intervention type: DEVICE
Intervention: S-ICD System
Study: NCT01507480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
Study: NCT00819117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy implant
Description: Device implant with appropriate leads

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy implant
Description: Device implant with appropriate leads
Study: NCT02861599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: speech therapy
Study: NCT00731471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
Study: NCT02576951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03466528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pabrinex
Description: standard treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pabrinex
Description: standard treatment
Study: NCT01790451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation
Study: NCT03104361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
Study: NCT02010489

Intervention type: OTHER
Group type: OTHER
Intervention: 12 week Exercise Program
Description: Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
Study: NCT02145715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study: NCT01505608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
Study: NCT01748825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
Study: NCT01505608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
Study: NCT00002704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT01748825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
Study: NCT02160691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anxiety Meter
Description: This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
Study: NCT03951558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet for calciuria prevention
Description: Dietary recommendations for water, salt, calcium and proteins according to age and DIR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydroclorothiazide recommendations for hypercalciuria
Study: NCT03903887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD1 antibody-activated TILs
Description: Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
Study: NCT02567994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teneligliptin
Description: Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
Study: NCT03181776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilting in 15 degrees
Description: The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilting in 30 degrees
Description: The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine position
Description: The mother will be placed in standard supine position
Study: NCT01952041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: Smartphone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT02138864

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FP-(+)-DTBZ
Description: no available